摘要
目的周剂量伊立替康(CPT-11)联合5-氟尿嘧啶(5-FU)及醛氢叶酸(LV)组成二线化疗方案,观察一线化疗失败后的晚期转移性结直肠癌疗效及毒性反应。方法入组病例为转移性结直肠癌经一线化疗失败后的患者,CPT-1160mg/m2,LV100mg/m2,5-FU500mg/m2,每周1次,连续3周,每4周重复,每例至少接受2个周期化疗后评价疗效,患者最多接受6个周期。观察缓解率、安全性及生存期。结果全组30例,CR0例,PR8例(26.7%),SD9例(30.0%),PD13例(43.3%),总有效率(CR+PR)为26.7%。中位疾病进展时间(TTP)4.8个月,中位生存期(MOS)9.2个月,治疗相关性毒副反应主要是Ⅲ～Ⅳ度迟发性腹泻,发生率为23.3%。结论周剂量CPT-11联合5-FU/LV为治疗晚期转移性结直肠癌有效的二线方案,患者对毒副反应可以耐受,可供临床安全使用。
Objective To investigate the efficacy and safety of weekly dose of irinotecan （CPT-11） combined with fluorouracil and leucovorin as the second-line therapy for metastatic colorectal cancer （mCRC） after first-line chemotherapy by using FOLFOX regimen until progression or unacceptable toxicity. Methods Patients received CPT-11 60mg/m2 as a 90-minute iiffusion,LV 100mg/m2 iv infusion for 2h and fluorouracil 500mg/m^2 iv infusion for 6h on days 1,8 and 15 with 4 week as a cycle,with 6 cycles as a maximum. Tumor assessment was done every 2 cycles,including the efficacy,safety and survival time. Results In all 30 cases of mCRC,none reached complete response,8 partial response （26.7%）,9 stable disease（30.0%）,and 13 progression after treatment（43.3%）. The response rate of the whole group was 26.7%. The median disease progress time was 4.8 months and the median survival time was 9.2 months. And the the treatment related toxicity side reaction was delayed diarrhea （grades Ⅲ to Ⅳ,23.3%）. Conclusion Weekly dose of irinotecan（CPT-11）combined with fluorouracil and leucovorin is effective and has tolerable toxicity as second-line therapy for ⅢCRC,which can be used safely.
出处
《中国现代医生》
2010年第32期10-11,共2页
China Modern Doctor
